Premier Alternatives

LabGenius Therapeutics

London, United Kingdom · Founded 2012 · Privately Held (backing)

Developer of next-generation protein-based therapeutics designed to address unmet needs like inflammatory bowel disease. LabGenius Therapeutics is based in London, United Kingdom and was founded in 2012. Its last reported valuation was $85.9 million in Jul 2025. It has raised $93.4 million.

Last reported valuation
$85.9M
Oct 2026
Priced at
—
Total raised
$93.4M
Last round
—

LabGenius Therapeutics key facts

as of Oct 2026
  • Developer of next-generation protein-based therapeutics designed to address unmet needs like inflammatory bowel disease.
  • LabGenius Therapeutics is valued at approximately $85.9M as of Oct 2026 (last reported valuation).
  • It has raised $93.4M; the latest was Later Stage VC ($13.5M) in Jul 2025.
  • Notable investors include Innovate UK, Lux Capital, Felicis, Octopus Ventures, Kevin Moore — 35 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$85.9M

LabGenius Therapeutics's last reported valuation, Jul 2025. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of LabGenius Therapeutics with a free account
  • ·The complete investor list: 35 names
  • ·Watch LabGenius Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

LabGenius Therapeutics funding rounds

No rounds on record

No funding rounds for LabGenius Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

LabGenius Therapeutics valuation

LabGenius Therapeutics's last reported valuation was $85.9 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.

LabGenius Therapeutics investors

35 investors are on record for LabGenius Therapeutics, including Innovate UK, Lux Capital, Felicis and Octopus Ventures. By type, the record holds 8 venture capital firms and 2 private investors.

About LabGenius Therapeutics

Developer of next-generation protein-based therapeutics designed to address unmet needs like inflammatory bowel disease. The company's therapeutics engineer protein drugs properties, such as protease stability and tissue penetration, using their smart robotic platform to design, conduct, and critically learning from its experiments, enabling physicians to get access to protein therapeutics that are developed using robotic automation, synthetic biology, and advanced machine learning.

Sector
Healthcare
HQ
London, United Kingdom
Founded
2012
Employees
66
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.